The lawsuit seeks a ruling that Stemina’s services directly infringe on US patents related to global analysis of complex biological samples for the discovery of biomarkers and pathways associated with drug action, toxicity and disease, according to the company.
Metabolon, through the lawsuit, requests for monetary damages in addition to an order permanently enjoining Stemina from continued acts of infringement.
Metabolon has developed the technology to identify and measure all of the biochemicals in a biological sample through its proprietary global processing method.